Highlights Medy-Tox Inc.

Equities

A086900

KR7086900008

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-23 EDT			5-day change	1st Jan Change
127,500 ^KRW	-0.39%		-4.35%	-47.10%

03-21	Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-05	South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Medytox, Inc. Announces the Formation of Luvantas Subsidiary	01-03	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20	CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	22-12-12	CI
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.	22-09-26	CI
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.	22-09-21	CI
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.	22-08-17	CI
Medy-Tox Inc. authorizes a Buyback Plan.	22-08-16	CI
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.	22-07-07	CI
Medy-Tox Inc.'s Equity Buyback announced on June 7, 2022, has closed with 39,777 shares, representing 0.66% for KRW 4,574.17 million.	22-07-05	CI
Medy-Tox Inc. announces an Equity Buyback for 39,777 shares.	22-06-07	CI
Medy-Tox Inc. authorizes a Buyback Plan.	22-06-06	CI
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on February 18, 2022.	22-04-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medy-Tox Inc.

Equities

A086900

KR7086900008

Highlights

Filters